Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
56 participants
INTERVENTIONAL
2017-04-10
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00235820
A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate
NCT01251614
Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy
NCT00368654
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00237887
Mechanism of Action Study for Psoriasis
NCT00932113
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Compare anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX. ADA is a fully human monoclonal antibody to TNF-a. More recent advances in detection of ADA antibodies have shown that many patients develop antibodies to ADA while on treatment and some of these antibodies are neutralizing. The presence of anti-ADA antibodies has been correlated with loss of therapeutic response in many disease states.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ADA and Placebo
Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks
Adalimumab
Subcutaneous Injection
Placebo
Oral Tablet
ADA and MTX
Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks
Adalimumab
Subcutaneous Injection
Methotrexate
Oral Tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adalimumab
Subcutaneous Injection
Methotrexate
Oral Tablet
Placebo
Oral Tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject must have ≥ 10% body surface area involvement
3. Subject must have psoriasis area and severity index (PASI) ≥12
4. Subject has stable psoriasis of at least six months' duration
5. Male subjects must agree to use a reliable form of birth control during the study and for 180 days after the last dose of study drug. Male subjects must not donate sperm during the study or for 180 days after the last dose of study drug. If female, subject is either not of childbearing potential (postmenopausal for at least 1 year or surgically sterile) or is of childbearing potential and is using approved method of birth control throughout study and for 180 days after last dose of study drug. Approved methods of birth control include the following:
1. Condoms, sponge, foams, jellies, diaphragm, or intrauterine device (IUD)
2. Hormonal contraceptives for 90 days prior to study drug administration
3. A vasectomized partner
6. Subject has negative PPD tuberculosis skin test at screening assessment.
7. Subject must be able and willing to provide written informed consent and comply with requirements of this study protocol.
Exclusion Criteria
2. Any previous exposure to ADA including biosimilar ADA
3. Moderate to high strength topical steroids (class 4 or greater) or Vitamin D analogues within one week of study entry
4. Oral systemic therapy (methotrexate, cyclosporine, apremilast, acitretin) within 8 weeks of study entry
5. Previous intolerance or adverse reaction to MTX
6. Phototherapy of any type within 4 weeks of study entry (narrowband UVB, psoralen-UVA, 308 nM LASER, commercial tanning units)
7. IL-12/23 inhibitors (ustekinumab) and any IL-23 inhibitor (guselkumab, tildrakizumab, risankizumab) within 12 weeks of baseline
8. Other biologic agents within 8 weeks of study entry
9. History of chronic liver disease, hepatitis, or alcohol abuse
10. Chronic use of any concomitant medication which has a significant potential for interaction with MTX (e.g. sulfa antibiotics, chronic non-steroidal anti-inflammatory (NSAID) use)
11. History of tuberculosis, opportunistic infections, or any active infection at screening
12. Elevated liver enzymes (AST, ALT, ≥1.5 times normal at screening)
13. Serum creatinine ≥1.5 (at screening)
14. Any other laboratory abnormality that would pose a concern for the investigator
15. Daily alcohol use or consumption of more than four alcoholic drinks (4 ounces) in one 24 hour period
16. Patients who test positive for hepatitis B or C exposure (previous vaccination to Hepatitis B is allowed)
17. Cancer within the last five years is exclusionary with the exception of treated cutaneous basal cell carcinoma or squamous cell carcinoma or low-grade cervical intraepithelial neoplasia.
18. Any patient that is deemed by the investigator to be at a safety risk for the intervention in this trial.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Jeffrey J Crowley MD
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jeffrey J Crowley MD
Jeffrey J Crowley, MD, Prinicipal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey J Crowley, MD
Role: STUDY_DIRECTOR
Bakersfield Dermatology and Skin Cancer Medical Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bakersfield Dermatology and Skin Cancer Medical Group
Bakersfield, California, United States
Clinical Science Institute
Santa Monica, California, United States
DermAssociates, PC
Rockville, Maryland, United States
Modern Research Associates, PLLC
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A16-241
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.